Doug: < AMLN > The Numbers, The Insider Buying / Selling, and all that other stuff....
*** I called the company today, earnings will be out before the end of the month. *****
PROFESSIONAL INVESTOR REPORT
02/17 Analysts' Ratings: Pharmaceuticals
This is a weekly ranking of the stocks within the
Pharmaceuticals industry, based on analysts'
recommendations contributed within the past month to First
Call's database. To be included on the list, a company must
be rated by at least five analysts.
Also included in the list are First Call analysts'
estimates for the companies' current quarters. Estimates are
operating income per share based on a survey of analysts.
First Call Consensus Recommendation Scale
1.0-2.4 = Buy
2.5-3.4 = Hold
3.5-5.0 = Sell
Latest # Analysts First Call # Analysts
Consensus Covering EPS Estimate Covering
--------- ---------- ------------ ----------
(AMLN) 2.0 5 ($0.59) 4Q 5
(END) Dow Jones Newswires 02-17-98
08:19 AM EST
********************************************************
***MOST RECENT INSIDER BUYS AND SELLS. NOTE THE BUYS ARE OPEN MARKET BUYS!! The RECENT SELLS ARE MOSTLY A YEAR AGO! GOOD SIGNS HERE!!***
INSIDER BUYING AMYLIN PHARMACEUTICALS INC.
NAME DIRECT
TITLE DATE SHARES SHARE TOTAL OR
TRANSACTION TYPE BOUGHT BOUGHT PRICE HOLDINGS INDIRECT
HAUGEN RICHARD M
OFFICER 12/22/97 5,000 5.00 37,061 I
OPEN MARKET PURCHASE COM
GREEN HOWARD E
CHAIRMAN OF THE BD 12/18/97 10,000 5.00 1,535,667 I
OPEN MARKET PURCHASE COM
GREENE HOWARD E JR
CHAIRMAN OF THE BD 08/22/97 5,000 7.25 1,535,568 I
OPEN MARKET PURCHASE COM
GREENE HOWARD E JR
CHAIRMAN OF THE BD 08/18/97 5,000 8.00 1,530,568 I
OPEN MARKET PURCHASE COM
******************************
INSIDER SELLING AMYLIN PHARMACEUTICALS INC.
------------------------------------------------------------------------
NAME DIRECT
TITLE DATE SHARES SHARE TOTAL OR
TRANSACTION TYPE SOLD SOLD PRICE HOLDINGS INDIRECT
DUFT BRADFORD J
VICE PRESIDENT 12/18/97 4,240 5.06 221,490 D
OPEN MARKET SALE COM
WOLLAEGER TIMOTHY J
DIRECTOR 02/14/97 160,000 N/A 0 I
OTHER DISPOSITION COM
OLSEN KARL H
OFFICER 01/17/97 547 14.00 -- D
OPEN MARKET SALE COM
OLSEN KARL H
OFFICER 01/16/97 1,500 14.00 -- D
OPEN MARKET SALE COM
********
FEDERAL FILINGS
01/09 Insiders Buy AMYLIN PHARMACEUTICALS INC. Stock
FORM 4
ISSUER: AMYLIN PHARMACEUTICALS INC.
SYMBOL: AMLN
FILER: GREENE JR HOWARD E
TITLE: Chairman of the Board
PURCHASED: 12/18/97 10,000 5.00
OWNERSHIP: 1,535,667
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
ISSUER: AMYLIN PHARMACEUTICALS INC.
SYMBOL: AMLN
FILER: HAUGEN RICHARD M
TITLE: President
PURCHASED: 12/22/97 5,000 5.00
OWNERSHIP: 37,061
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
(END) FEDERAL FILINGS-DOW JONES NEWS 01-09-98
06:06
**************************************************************
** NOTE THE MANY SHARES THAT JOHNSON AND JOHNSON HAVE! **
WATCH AMYLIN PHARMACEUTICALS INC
LIST OF 5% OWNERS AND RECENT HOLDINGS
NAME TOTAL FILING LAST STOCK
HOLDINGS TYPE FILING TYPE
DATE
DOMAIN TECHNOLOGY INC 1,410,894 13G 02/08/96 COM
GREENE HOWARD E 1,399,097 13G 02/14/94 COM
GREFENSTETTE CG 2,126,080 13D 08/15/94 COM
JOHNSON & JOHNSON 3,455,407 13D 11/06/96 COM
JOHNSON & JOHNSON 1,893,868 13D 10/06/95 COM
***************************************************************
(S&P) 11/12/97 (AMLN) PAGE 1 OF 1
Amylin Pharmaceuticals: SUMMARY
Focused on developing novel medicines
for treating diabetes and related
metabolic disorders; collaborating with
Johnson & Johnson to develop
pramlintide, a chemical analog of human
amylin, with the aim of improving
glucose control for people with
diabetes who use insulin... 9 mos. '97
loss widened despite 32% higher
revenues... hurt by larger R&D
expenses. Tel.# 619-552-2200
*****************************************************************
** SOMETHING TO NOTE: Shares Held by Institutions 9,344,000
Number of Institutions Holding 92
% of Shares Held by Institutions 28.9
WOW!
*****
Financial Profile
Data current through 02/17/1998
Amylin Pharmaceuticals
9373 Towne Centre Dr
San Diego, CA 92121
Telephone: (619) 552-2200
Fax: (619) 552-2212
Dow Jones Industry Group: Pharmaceuticals
Business Description: Focused on developing novel therapeutics
for treating people with metabolic disorders. Conducting a
series clinical trials of its lead drug candidate,
Pramlintide, which is being developed to improve glucose
control in Type I & II diabetes.
Primary SIC: 2834
SIC Codes: 8731
Stock Symbol: AMLN
Exchange: NASDAQ
CEO: Richard M. Haugen
Employees: 214
Auditors: Ernst & Young LLP
Latest Report: Unqualified
Share Data
Latest Reported Shares Outstanding 32,252,000
Latest Shares Outstanding Date 11/25/1997
Latest Balance Sheet Shares Outstanding 32,252,000
Short Interest Shares 597,796
Short Interest Ratio 1.9 Days
Short Interest Ratio Date 01/08/1998
Net Insider Transactions 10,760
Net Insider Transactions Date 12/31/1997
Shares Held by Institutions 9,344,000
Number of Institutions Holding 92
% of Shares Held by Institutions 28.9
Institutional Holding Date 01/31/1998
Market Value($ Mil) 188
Market Value as % Revenues 526
Stock Price ($) And Volume
Most Recent Close Price 5.84
Most Recent Close Price Date 02/17/1998
Close Price 4 Weeks Ago 4.88
Close Price 13 Weeks Ago 6.50
Close Price 26 Weeks Ago 7.25
Close Price 52 Weeks Ago 15.75
Price Change Last Month 11.2%
Price Change Last 10 Days 6.2%
Price Change Last 26 Weeks -19.4%
Price Change Last 52 Weeks -62.9%
Price Change YTD 7.4%
Price Change vs Market Last Trading Week 99%
Price Change vs Market Last 4 Weeks 112%
Price Change vs Market Last 13 Weeks 85%
Price Change vs Market Last 26 Weeks 73%
Price Change vs Market Last 52 Weeks 29%
Price Change vs Market YTD 102%
4-Week High Price 5.94
4-Week Low Price 4.25
13-Week High Price 7.00
13-Week Low Price 4.25
26-Week High Price 9.88
26-Week Low Price 4.25
52-Week High Price 16.31
52-Week Low Price 4.25
YTD High Price 6.38
YTD Low Price 4.25
5-Day Moving Avg Price 5.75
10-Day Moving Avg Price 5.47
10-Week Moving Avg Price 5.39
30-Week Moving Avg Price 8.06
200-Day Moving Avg Price 9.24
Beta, Up Market 2.48
Beta, Down Market 0.81
Shares Traded This Week 94,300
Volume as % of Shares Outstanding 0.29%
Avg Daily Volume Last 2 Weeks 133,700
Avg Daily Volume Last 4 Weeks 142,700
Avg Daily Volume Last 13 Weeks 212,600
Avg Daily Volume Last 26 Weeks 291,400
Avg Daily Volume Last 52 Weeks 295,300
Avg Daily Volume YTD 142,000
On-Balance Volume Index Last 4 Weeks 80%
Liquidity Ratio 33,150
P/E Ratio NE
5-Year High P/E NC
5-Year Low P/E NC
Selected Balance Sheet Items ($ Mil)
Fiscal Year End 12/31/1996 12/31/1995 12/31/1994 12/31/1993
Cash & Equivalent 42.7 16.7 7.4 10.1
Receivables 0.0 0.0 0.0 0.0
Inventories 0.0 0.0 0.0 0.0
Current Assets 65.4 55.0 30.4 57.4
Gr Fixed Assets 14.9 11.6 9.6 5.8
Accum Depr & Depl 8.1 5.8 3.8 2.2
Net Fixed Assets 6.8 5.8 5.8 3.6
Total Assets 73.5 61.9 37.3 62.0
Accounts Payable 4.8 1.5 1.2 0.5
Short-Term Debt 1.3 0.8 0.9 0.6
Curr Liabilities 18.7 9.7 4.2 3.0
Long-Term Debt 6.3 2.4 2.2 0.8
Total Liabilities 25.0 12.2 6.4 3.9
Preferred Equity 0.0 0.0 0.0 0.0
Common Equity 48.5 49.8 30.9 58.2
Retained Earnings -155.1 -117.3 -88.0 -53.5
Total Equity 48.5 49.8 30.9 58.2
Liabs & Equity 73.5 62.0 37.3 62.1
Working Capital 46.7 45.2 26.2 54.4 |
